Image
 

Locate Available Clinical Trials

To view available Clinical Trial information choose from the list on the right or search using the fields below.

 

 

trial #
trial description
  • Alliance A081105
  • The purpose of this study is to compare any good and bad effects patients may have when treated with the standard treatment against patients who are treated with the standard treatment plus erlotinib (a research drug) for patients who have early stage non-small cell lung cancer that was surgically removed and may have been treated with chemotherapy and/or radiation.

  • Alliance A151216
  • The purpose of this research study is to examine lung cancer patients’ surgically removed tumors for certain genetic changes, and to possibly refer these patients to a treatment study with drugs that may specifically target tumors that have these genetic changes. 

  • Alliance A211401
  • The purpose of this study is to see if post-operative complications can be reduced by helping patients stop smoking with a drug called varenicline (also called Chantix®) and using National Cancer Institute Tobacco Quitline for counseling. This study will see how well the drug varenicline helps you stop smoking by comparing it to a placebo. A placebo is a pill that looks like the study drug but contains no medication.

  • Alliance A221504
  • The purpose of this study is to test the safety and effects of naloxegol. Naloxegol is a medicine that blocks the actions of opioids outside the brain, without interfering with the pain-relieving effect of opioids inside the brain. The researchers want to see if naloxegol will relieve some of the side effects of the opioid pain medications you are taking. They also want to see if naloxegol fights off future growth in the cancer that you have, whether or not you are taking pain medications.

  • CALGB 30610
  • The purpose of this study is to compare the effects, good and/or bad, of three different ways to give radiation therapy for limited small cell lung cancer. Two of the ways are research, while one of them is standard. The two research ways of giving the radiation therapy are (1) once a day (Monday through Friday) with a high dose of radiation for 7 weeks; or (2) once a day (Monday through Friday) for 16 days of treatment (about 3 weeks), followed by twice a day for the remaining 9 days of treatment (about 2 weeks), for a total of 5 weeks. The standard way of giving the radiation therapy is to give it twice a day (Monday through Friday) for 3 weeks. Everyone will get the chemotherapy with cisplatin and etoposide, which has been established through clinical trials to be standard drugs (chemotherapy) for this type of cancer.

  • CTSU EA5142
  • The purpose of this study is to find if adding the study drug, nivolumab (also known as OPVIDO®), will limit lung cancer from growing back in patients with early stage non-small cell lung cancer. Nivolumab is a drug that may turn on the body’s immune system to attack any cancer cells that may remain after surgery. The addition of nivolumab may help prevent your cancer from returning, but it could also cause side effects. This research study will allow researchers to find out whether this different treatment is better, the same, or worse than the usual treatment for lung cancer. The study drug, nivolumab, is already FDA-approved for use in non-small cell lung cancer that has previously been treated with chemotherapy. The use of nivolumab in this study is investigational (not approved by the FDA) in your type of cancer.

  • CTSU EA5152
  • The purpose of this research study is to compare any good and bad effects of using nivolumab alone, nivolumab plus cabozantinib, or nivolumab plus cabozantinib plus ipilimumab. Nivolumab is approved for use in advanced lung cancer.  Cabozantinib and Ipilimumab are approved for the treatment of cancers, but not advanced lung cancer. The combinations used in this trial are investigational. The addition of these investigational drugs to a usual treatment (nivolumab) could shrink your cancerous tumor and/or prevent it from returning but it could also cause side effects. This research study will assist the researchers in determining whether these different approaches (nivolumab plus cabozantinib and ipilimumab or nivolumab plus cabozantinib) is better, the same, or worse than a usual approach (nivolumab alone) in treating your form of advanced lung cancer. To be better, the study drugs should improve how long you are able to stay on this treatment by more than 3 months compared to a usual approach of nivolumab alone.

     

  • CTSU EA5161
  • The purpose of this research study is to compare any good and bad effects of using nivolumab (OPDIVO®) along with the usual chemotherapy regimen of cisplatin/carboplatin and etoposide to using the usual chemotherapy approach alone. Nivolumab is a drug that may turn on the body’s immune system to attack cancer cells. The addition of nivolumab to the usual chemotherapy could shrink your cancer and could delay it from returning but it could also cause side effects. This research study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach. To be better, the study drug/study approach should improve how long you are able to live with your cancer under control by approximately 3 or more months compared to the usual approach.  

     

  • CTSU EA5162
  • The purpose of this study is to test any good and bad effects of the study drug called osimertinib. Osimertinib could shrink your tumor but it could also cause side effects. Researchers hope to learn if the study drug will shrink the tumor by at least one-quarter compared to its present size. Osimertinib is FDA-approved (Food and Drug Administration approved) to treat other types of lung cancer. The study is testing the effects of a higher dose (160 mg) of osimertinib than the dose approved by the FDA (80 mg.)

     

  • CTSU EA6141
  • The purpose of this research study is to compare any good and bad effects of giving ipilimumab, nivolumab, and GM-CSF (Sargramostim) at the same time compared to just ipilimumab and nivolumab together. We would also like to find out what effects, good and bad, that this combination of drugs may have on your cancer.

  • ECOG-ACRIN E4512
  • The purpose of this research study is to compare any good and bad effects of using the study drug, crizotinib (also known as XALKORI®), after completion of surgery and, in some cases, after chemotherapy and/or radiation therapy for ALK-positive non-small cell lung cancer.

  • NRG LU002
  • RTOG 1308
  • The purpose of this study is to compare the good and bad effects of these two different types of radiation therapy in combination with FDA-approved chemotherapy for your type of lung cancer. Compared with photons, proton therapy can stop shortly after penetrating through the tumor and therefore may cause less damage to the surrounding healthy organs. This feature of proton therapy may allow doctors to deliver higher doses of radiation to the tumor. 

  • SWOG S1400
  • The purpose of this study is to compare several investigational agents to the usual treatment approach for squamous cell lung cancer that has progressed.  The investigational drug assigned will be based on tumor biomarkers.

     

  • SWOG S1619